Table 2.
Baseline characteristics of the strategic treatment group and mismatched treatment group
| Variables | Strategic treatment (n=17) | Mismatched (n=17) | p value |
|---|---|---|---|
| Age (years) | 53.2±16.0 | 58.4±10.8 | 0.5016 |
| Male, n (%) | 12 (70.5) | 6 (35.3) | 0.0084 |
| Disease duration (months) | |||
| PSO | 108 (42, 288) | 216 (10, 258) | 0.9176 |
| PsA | 42 (13.5, 116.5) | 43 (16.5, 144) | 0.7960 |
| Peripheral arthritis | 17 (100) | 17(100) | 1.0000 |
| Spinal involvement | 4 (23.5) | 6 (35.2) | 0.7080 |
| History of past bDMARDs | 1st 12 (70.5) | 1st 12 (70.5) | 1.0000 |
| Concomitant MTX use | 12 (70.6) | 10 (58.8) | 0.7270 |
| bDMARDS initiated | |||
| IL-17-i/TNF-i | 6 (35.2)/11 (64.7) | 8 (47.0)/9 (52.9) | 0.4905 |
| Disease activity | |||
| TJC | 7 (5, 8.5) | 8 (3.5, 14) | 0.4164 |
| SJC | 6 (4, 12.5) | 5 (2.5, 7) | 0.1453 |
| CRP (mg/dl) | 0.99 (0.18, 2.14) | 0.54 (0.075, 1.71) | 0.2347 |
| DAPSA | 24.1 (19.2, 33.7) | 31.2 (20.9, 39.8) | 0.1848 |
| PASI | 3.1 (0.5, 5.75) | 1.6 (0.4, 6.3) | 0.7823 |
Data are expressed as mean ± standard deviation, median (interquartile range [IQR]), or number (%)
TNF-i TNF inhibitors, IL-17-i IL-17 inhibitors, TJC tender joint counts 68, SJC swollen joint counts 66, DAPSA Disease Activity in Psoriatic Arthritis, PASI Psoriasis Area and Severity Index
*p<0.05, by Mann-Whitney U test or chi-square test